These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


373 related items for PubMed ID: 15708048

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA.
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A, Rais-Bahrami S, Peck HJ, Walsh PC, Epstein JI, Trock BJ, Gonzalgo ML.
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer.
    D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP.
    J Urol; 2001 Jan; 165(1):126-9. PubMed ID: 11125380
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
    Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, Shariat SF, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS.
    Urol Oncol; 2007 Jan; 25(4):291-7. PubMed ID: 17628294
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
    Shariat SF, Abdel-Aziz KF, Roehrborn CG, Lotan Y.
    Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS, Cookson MS, Coffey CS, Vader V, Roberts RL, Chang SS, Smith JA, Shappell SB.
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [Abstract] [Full Text] [Related]

  • 19. Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression.
    Aydin H, Tsuzuki T, Hernandez D, Walsh PC, Partin AW, Epstein JI.
    Urology; 2004 Sep; 64(3):551-5. PubMed ID: 15351591
    [Abstract] [Full Text] [Related]

  • 20. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
    Makarov DV, Humphreys EB, Mangold LA, Walsh PC, Partin AW, Epstein JI, Freedland SJ.
    J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 19.